Journal
NEUROLOGY
Volume 70, Issue 16, Pages 1418-1422Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/01.wnl.0000286942.14552.51
Keywords
-
Categories
Funding
- NIEHS NIH HHS [P01 ES016732-020004, R01 ES010544, R01 ES010544-03, U54 ES012078, R01 ES010544-01A1, P01 ES016732-01S10004, ES10544, R01 ES010544-05, P01 ES016732-010004, P01 ES016732, P30 ES007048, R01 ES013717, U54ES12078, 5P30 ES07048, R01 ES010544-04, R01 ES010544-02] Funding Source: Medline
Ask authors/readers for more resources
Objective: To investigate associations between statin (3-hxydroxy-3-methylglutaryl-coenzyme A reductase inhibitor) use and Parkinson disease (PD). Methods: We used a population-based design to recruit 312 incident idiopathic PD cases and 342 controls from three rural California counties. Results: We observed a higher frequency of statin use among controls vs cases (OR 0.45; 95% CI 0.29 to 0.71) and a strong dose-response relation. The strongest protective association between statin use and PD was observed in long- term (>= 5 years) users (OR 0.37; 95% CI 0.18 to 0.78). There was no difference by gender or age. We noted 60 to 70% risk reductions for each individual statin except pravastatin. Conclusion: Ascribing causality to these associations is premature and further studies are needed to confirm a potential neuroprotective role for statins in PD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available